Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 1.5% – Time to Buy?

Shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) rose 1.5% during mid-day trading on Tuesday . The stock traded as high as $2.07 and last traded at $2.04. Approximately 6,509 shares were traded during trading, a decline of 60% from the average daily volume of 16,332 shares. The stock had previously closed at $2.01.

Alaunos Therapeutics Trading Up 1.5 %

The company’s fifty day simple moving average is $2.53 and its two-hundred day simple moving average is $5.89.

Alaunos Therapeutics (NASDAQ:TCRT) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Alaunos Therapeutics

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. Virtu Financial LLC bought a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,440 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.10% of Alaunos Therapeutics at the end of the most recent quarter. 27.72% of the stock is owned by hedge funds and other institutional investors.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.